Binchen Mao, Sheng Guo, Frank Xing, Zhengzheng Bao, and Henry QX Li
Combination therapy provides the opportunity for increased efficacy and reduced toxicity and drug-resistance within clinical oncology treatment. It has become the standard treatment approach for many diseases and holds great promise for cancer indications of unmet medical need.
Therefore, being able to study combination regimens preclinically, and provide evidence of significant superiority over single agents alone, is of particular importance. To this end, CrownBio has developed a new bioinformatics tool, CrownSyn, to enable researchers to evaluate and quantify two-drug combination effects (synergistic, antagonistic, and additive) for in vitro cell assays.
CrownSyn analyzes data from two common drug combination designs, enabling rapid data input from existing combination studies or when designing future studies.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-02-19
2021-10-28
landing_page
PDX/Databases